The European Medicines Agency (EMA) has validated and is now reviewing Kite Pharma’s application requesting the approval of its investigational chimeric antigen ... Read more
Imbruvica (ibrutinib) in combination with rituximab continues to prolong survival and the time without disease progression in previously untreated adults with ... Read more
TG Therapeutics is seeking accelerated approval in the U.S. for its investigational oral therapy umbralisib to treat patients with marginal zone ... Read more
The European Commission has conditionally approved Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine, to treat people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more
Treatment with CS1001, an investigational immunotherapy, shows promising anti-tumor activity against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL) a rare ... Read more
MorphoSys is asking the U.S. Food and Drug Administration (FDA) to approve its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat ... Read more
A combination of Venclexta (venetoclax) and rituximab continues to significantly reduce the risk of disease progression or death in relapsed or refractory ... Read more
Bristol-Myers Squibb has asked the U.S. Food and Drug Administration (FDA) to approve its investigational CAR T-cell therapy lisocabtagene maraleucel (liso-cel) ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cellectar BioSciences‘ experimental therapy CLR 131 for lymphoplasmacytic ... Read more
